N-linked glycosylation is one of the most abundant posttranslational modifications of
membrane-bound proteins in eukaryotes and affects a number of biological activities …

Reactivation of T cell immunity by PD-1/PD-L1 immune checkpoint blockade has been
shown to be a promising cancer therapeutic strategy. However, PD-L1 …

Immunotherapies targeting programmed cell death protein 1 (PD-1) and programmed cell
death 1 ligand 1 (PD-L1) immune checkpoints represent a major breakthrough in cancer …

Protein glycosylation provides proteomic diversity in regulating protein localization, stability,
and activity; it remains largely unknown whether the sugar moiety contributes to …

Programmed-death ligand 1 (PD-L1) and its receptor programmed cell death 1 (PD-1)
mediate T cell–dependent immunity against tumors. The abundance of cell surface PD-L1 is …

The immune checkpoint molecules programmed cell death receptor 1 (PD-1) and
programmed death ligand 1 (PD-L1) are one of the most promising targets for tumor …

Posttranslational modifications (PTM) of PD-L1 have emerged as important regulatory
mechanisms that modulate immunosuppression in patients with cancer. In exposure to …

A growing amount of evidence suggests that ubiquitination and deubiquitination of
programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) play crucial roles in the …

Quantitative assessment of key proteins that control the tumor-immune interface is one of the
most formidable analytical challenges in immunotherapeutics. We developed a targeted MS …

PD‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of
PD‐1 with monoclonal antibodies (MA bs) to block the interaction with its ligand PD‐L1 has …